伴或不伴C9ORF72或ATXN2基因扩增的ALS病例脑组织TDP-43水平
该研究通过免疫印迹定量23例伴ATXN2或C9ORF72基因重复扩增的散发性ALS病例及10例对照的运动皮层、脊髓和小脑蚓部尸检脑组织中磷酸化(45 kDa)和非磷酸化(43 kDa)TDP-43水平。结果发现C9ORF72扩增ALS病例运动皮层磷酸化TDP-43显著增高,中间型ATXN2扩增ALS病例脊髓磷酸化TDP-43显著增高,但各组三个区域非磷酸化TDP-43水平相似。提示不同翻译后修饰参与遗传扩增病例病理性TDP-43生成。
要点
- C9ORF72扩增ALS病例运动皮层磷酸化TDP-43水平显著增高。
- 中间型ATXN2扩增ALS病例脊髓磷酸化TDP-43水平显著增高。
- 各组三个区域非磷酸化TDP-43水平相似。
核心结论
- 伴C9ORF72或ATXN2扩增的ALS病例中磷酸化TDP-43水平存在区域特异性差异,而非磷酸化TDP-43水平无差异,提示不同翻译后修饰参与病理性TDP-43生成。
研究设计与样本
- 免疫印迹定量23例伴ATXN2或C9ORF72基因重复扩增的散发性ALS病例和10例对照的运动皮层、脊髓和小脑蚓部尸检脑组织中45 kDa磷酸化TDP-43和43 kDa非磷酸化TDP-43。
主要发现
- C9ORF72扩增ALS病例运动皮层磷酸化TDP-43水平显著高于其他组。
- 中间型ATXN2扩增ALS病例脊髓磷酸化TDP-43水平显著高于其他组。
- 所有ALS组三个区域非磷酸化TDP-43水平相似。
临床怎么用
- 提示针对病理性TDP-43的治疗研究需考虑不同基因扩增病例的翻译后修饰差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the amount of phosphorylated and nonphosphorylated TAR DNA-binding protein 43 (TDP-43) in the motor brain regions of cases of amyotrophic lateral sclerosis (ALS) with and without repeat expansions in the ATXN2 or C9ORF72 genes. METHODS: The 45-kDa phosphorylated form of TDP-43 and 43-kDa nonphosphorylated form of TDP-43 were quantified by immunoblot in postmortem brain tissue from the motor cortex, spinal cord, and cerebellar vermis of 23 cases with ALS with repeat expansions in the ATXN2 or C9ORF72 genes and sporadic disease and 10 controls. RESULTS: Significantly greater levels of phosphorylated TDP-43 were identified in the motor cortex of cases with ALS with C9ORF72 expansions, and significantly greater amounts of phosphorylated TDP-43 were found in the spinal cord of cases with ALS with intermediate ATXN2 expansions. In contrast, however, similar levels of nonphosphorylated TDP-43 were found in all 3 regions between ALS groups. CONCLUSION: Despite its central role in the pathogenesis of ALS and the emergence of potential targets to modify its aggregation, TDP-43 levels have not been quantified in pathologically confirmed cases with ALS. The present results demonstrating significant differences in phosphorylated but not nonphosphorylated TDP-43 levels suggest that different posttranslational modifications are involved in the generation of greater pathologic TDP-43 levels identified here in our cohort of cases with genetic expansions. These findings are consistent with emerging studies implicating distinct pathomechanisms in the generation of pathologic TDP-43 in cases with ALS with C9ORF72 or ATXN2 expansions and are of relevance to therapeutic research aimed at reducing pathologic TDP-43 in all or a subset of patients with ALS.
引用
- Yang Y, Halliday GM, Kiernan MC, et al. TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. Neurology. 2019. PMID: 31619481. doi:10.1212/WNL.0000000000008439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。